Patent Application
20240228490
The present invention belongs to the field of biomedicine, and specifically relates to a heterocyclic derivative inhibitor, a method for preparing the same, and a use thereof.
Poly(ADP-ribose) polymerase (PARP) is a protein superfamily that catalyzes the ribosylation of protein ADP in eukaryotic cells, including at least 17 protein subtypes. PARP can catalyze the cleavage of the substrate nicotinamide adenine dinucleotide NAD+ into nicotinamide and ADP-ribose, and enable the poly ADP-ribosylation of its target protein. PARP is located in the nucleus, and is a key enzyme in the repair of cellular DNA damage.
PARP1 is the earliest found and most studied PARP subtype, including three main domains, namely the N-terminal DNA-binding domain (DBD), the auto modification domain (AMD) and the C-terminal catalytic domain. PARP1 is an important functional protein in the process of DNA damage repair, and is a sensor of DNA single-strand damage. DNA damage can lead to PARP1 activation, poly-ADP-ribosylation modification of its target proteins such as histones, and recruitment of related repair proteins to promote DNA damage repair. PARP1 is very important for the stability of the genome of normal cells. However, in tumor therapy, PARP1 can antagonize the tumor killing effect produced by radiotherapy and chemotherapy by repairing the DNA of tumor cells damaged by radiotherapy and chemotherapy. Therefore, PARP1 inhibitors can be developed as sensitizers for tumor radiotherapy and chemotherapy.
Breast cancer susceptibility gene (BRCA) is an important tumor suppressor gene, which mainly includes two subtypes, BRCA1 and BRCA2. BRCA plays an important role in the repair of double-strand break DNA in DNA homologous recombination. Tumor cells often suffer from BRCA deficiency, which leads to the loss of double-strand break DNA damage repair function. If the function of PARP1 is simultaneously lost or inhibited, the repair of single-strand DNA damage will also be lost, which will eventually lead to the death of tumor cells and produce a “synthetic lethal” effect. Therefore, the use of PARP1 inhibitors blocks the repair function of the single-strand break DNA damage, which has a selective killing effect on BRCA-deficient tumors.
Currently, PARP inhibitors have achieved great success in the precision therapy of tumors, especially for tumors with BRCA mutations or defects. Currently marketed PARP inhibitors include Olaparib (AZD2281) from AstraZeneca, Rucaparib (CO-338) from Clovis, Niraparib (MK-4827) from Tesaro and Talazoparib (BMN-673) from Pfizer. The indications thereof are mainly ovarian cancer and breast cancer with BRCA mutations. There are also many PARP inhibitors in the clinical research stage. In the PARP family, PARP2 has the highest homology with PARP1. Therefore, most of the PARP inhibitors currently on the market or in the clinical stage are non-selective PARP inhibitors, which have potent inhibitory effects on both PARP1 and PARP2 subtypes. Studies have shown that PARP2 plays an important role in regulating red blood cell production. Inhibition of PARP2 is closely related to the clinical side effects of PARP inhibitor such as hematotoxicity, e.g., anemia.
The objective of the present invention is to provide a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, wherein the structure of the compound of formula (I) is as follows:
In some embodiments of the present invention, the compound is further as shown in formula (III):
In some embodiments of the present invention, the compound of formula (I) is a compound of formula (II):
In some embodiments of the present invention, the compound of formula (I) is a compound of formula (IV):
In some embodiments of the present invention, ring C is a 3 to 10 membered heterocyclyl, and preferably, ring C is a 4 to 8 membered heterocyclyl; the heteroatoms in the 3 to 10 membered heterocyclyl and 4 to 8 membered heterocyclyl are each independently selected from the group consisting of nitrogen, oxygen and sulfur, and the number of heteroatoms is independently 1, 2 or 3; preferably, the rings of the 3 to 10 membered heterocyclyl and 4 to 8 membered heterocyclyl are each independently monocyclic ring, bridged ring, spiro ring or fused ring.
In some embodiments of the present invention, ring C is
In some embodiments of the present invention, ring C is
In some embodiments of the present invention, ring C is
In some embodiments of the present invention, ring D is a 6 to 10 membered heterocyclyl, C6-10 aryl or 5 to 10 membered heteroaryl; more preferably, ring D is a 5 membered heteroaromatic ring, 6 membered heteroaromatic ring, benzene ring, 5 membered heteroaromatic ring fused with 6 membered heteroaromatic ring, 6 membered heteroaromatic ring fused with 6 membered heteroaromatic ring, 6 membered heteroaromatic ring fused with 6 membered heterocyclic ring, 6 membered heteroaromatic ring fused with 5 membered heterocyclic ring, benzene ring fused with 5 membered heterocyclic ring, benzene ring fused with 6 membered heteroaromatic ring, benzene ring fused with 6 membered heterocyclic ring; wherein the heteroatoms in the 3 to 14 membered heterocyclyl, 6 to 10 membered heterocyclyl, 5 to 10 membered heteroaryl and 5 to 14 membered heteroaryl are each independently selected from the group consisting of nitrogen, oxygen and sulfur, and the number of heteroatoms is independently 1, 2 or 3.
In some embodiments of the present invention, ring D is the following groups:
In some embodiments of the present invention, ring D is selected from the group consisting of:
In some embodiments of the present invention, ring D is
In some embodiments of the present invention, ring D is
In some embodiments of the present invention, ring D is
In some embodiments of the present invention, R1 is selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, cyano, amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl, 5 to 12 membered heteroaryl, —(CH2)nR11, —(CH2)nOR11, —(CH2)nC(O)R11, —(CH2)nC(O)OR11, —(CH2)nS(O)mR11, —(CH2)nNR22R33, —(CH2)nNR22C(O)OR33, —(CH2)nNR22C(O)(CH2)n1R33, —(CH2)nNR22C(O)NR22R33, —(CH2)nC(O)NR22(CH2)n1R33, —OC(R11R22)n(CH2)n1R33 and —(CH2)nNR22S(O)mR33, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl can be each optionally further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, nitro, hydroxy, thiol, cyano, amino, oxo, C1-6 alkyl, C1-6 alkoxy, C6-12 aryl, 5 to 12 membered heteroaryl and 3 to 12 membered heterocyclyl.
In some embodiments of the present invention, R1 is selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, cyano, amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl, 5 to 12 membered heteroaryl, —(CH2)nR11, —(CH2)nOR11, —(CH2)nC(O)R11, —(CH2)nC(O)OR11, —(CH2)nS(O)mR11, —(CH2)nNR22R33, —(CH2)nNR22C(O)OR33, —(CH2)nNR22C(O)(CH2)n1R33, —(CH2)nNR22C(O)NR22R33, —(CH2)nC(O)NR22(CH2)n1R33, —OC(R11R22)n(CH2)n1R33 and —(CH2)nNR22S(O)mR33, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl can be each optionally further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, amino, C1-6 alkyl and 3 to 12 membered heterocyclyl.
In some embodiments of the present invention, R11, R22 and R33 are each independently selected from the group consisting of hydrogen, deuterium, halogen, amino, hydroxy, cyano, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 hydroxyalkyl, cyano-substituted C1-6 alkyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl, 5 to 12 membered heteroaryl, —O(CH2)n1R66, —OC(R44R55)m1(CH2)n1R66, —NR44(CH2)n1R66, —(CH2)n1—, —(CH2)n1R66, —(CH2)n1OR66, —(CH2)n1SR66, —(CH2)n1C(O)R66, —(CH2)n1C(O)OR66, —(CH2)n1S(O)m1R66, —(CH2)n1NR44R55, —(CH2)n1C(O)NR44R55, —(CH2)n1NR44C(O)R66 and —(CH2)n1NR44S(O)mR66, each optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, amino, hydroxy, cyano, nitro, C1-6 alkyl and C3-12 cycloalkyl.
In some embodiments of the present invention, R44, R55 and R66 are each independently selected from the group consisting of hydrogen, deuterium, halogen, amino, hydroxy, cyano, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 hydroxyalkyl, cyano-substituted C1-6 alkyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl, each optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, amino, hydroxy, cyano, nitro, C1-6 alkyl and C3-12 cycloalkyl.
In some embodiments of the present invention, R1 is selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, cyano, amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl, each can be optionally further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, amino, C1-6 alkyl and 3 to 12 membered heterocyclyl.
In some embodiments of the present invention, R1 is selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, cyano, amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl.
In some embodiments of the present invention, R1 is selected from the group consisting of hydrogen, deuterium, cyano, C1-3 deuterated alkyl, C1-3 alkyl, C1-3 alkoxy, C3-6 cycloalkyl and 3 to 6 membered heterocyclyl, each can be optionally further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, amino, C1-3 alkyl and 3 to 6 membered heterocyclyl.
In some embodiments of the present invention, R1 is selected from the group consisting of hydrogen, deuterium, C1-3 deuterated alkyl, C1-3 alkyl, C3-6 cycloalkyl, 5 to 6 membered heteroaryl, 4 to 6 membered heterocyclyl and oxo-substituted 4 to 6 membered heterocyclyl.
In some embodiments of the present invention, R1 is selected from the group consisting of hydrogen, deuterium, C1-6 deuterated alkyl, C1-6 alkyl, C3-12 cycloalkyl and 3 to 12 membered heterocyclyl.
In some embodiments of the present invention, R1 is selected from the group consisting of hydrogen, —CH3, —CD3, —CH2CN, ethyl, methoxy, cyano, cyclopropyl,
In some embodiments of the present invention, R1 is selected from the group consisting of hydrogen, —CH3, —CD3 ethyl, methoxy, cyano, cyclopropyl,
In some embodiments of the present invention, R1 is selected from the group consisting of hydrogen, —CH3, —CD3, cyclopropyl,
In some embodiments of the present invention, each Ra is independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, oxo, cyano, amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl, 5 to 12 membered heteroaryl, —(CH2)nRa1, —(CH2)nORa1, —(CH2)nC(O)Ra1, —(CH2)nC(O)ORa1, —(CH2)nS(O)mRa1, —(CH2)nNRa2Ra3, —(CH2)nNRa2C(O)ORa3, —(CH2)nNRa2C(O)(CH2)n1Ra3, —(CH2)nNRa2C(O)NRa2Ra3, —(CH2)nC(O)NRa2(CH2)n1Ra3, —OC(Ra1Ra2)n(CH2)n1Ra3 and —(CH2)nNRa2S(O)mRa3, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl can be each optionally further substituted by one or more substituents selected from the group consisting of hydroxy, nitro, thiol, oxo, cyano, halogen, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, amino, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C6-10 aryl, 5 to 10 membered heteroaryl and 3 to 12 membered heterocyclyl.
In some embodiments of the present invention, each Ra is independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, oxo, cyano, amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl, 5 to 12 membered heteroaryl, —(CH2)nRa1, —(CH2)nORa1, —(CH2)nC(O)Ra1, —(CH2)nC(O)ORa1, —(CH2)nS(O)mRa1, —(CH2)nNRa2Ra3, —(CH2)nNRa2C(O)ORa3, —(CH2)nNRa2C(O)(CH2)n1Ra3, —(CH2)nNRa2C(O)NRa2Ra3, —(CH2)nC(O)NRa2(CH2)n1Ra3, —OC(Ra1Ra2)n(CH2)n1Ra3 and —(CH2)nNRa2S(O)mRa3, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl can be each optionally further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, amino, C1-6 alkyl and 3 to 12 membered heterocyclyl.
In some embodiments of the present invention, each Ra is independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, oxo, cyano, amino, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 alkoxy, C2-3 alkenyl, C2-3 alkynyl, C3-6 cycloalkyl, 3 to 6 membered heterocyclyl, C6-10 aryl, 5 to 10 membered heteroaryl, —(CH2)nRa1, —(CH2)nORa1, —(CH2)nC(O)Ra1, —(CH2)nC(O)ORa1, —(CH2)nS(O)mRa1, —(CH2)nNRa2Ra3, —(CH2)nNRa2C(O)ORa3, —(CH2)nNRa2C(O)(CH2)n1Ra3, —(CH2)nNRa2C(O)NRa2Ra3, —(CH2)nC(O)NRa2(CH2)n1Ra3, —OC(Ra1Ra2)n(CH2)n1Ra3 and —(CH2)nNRa2S(O)mRa3, the amino, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 alkoxy, C2-3 alkenyl, C2-3 alkynyl, C3-6 cycloalkyl, 3 to 6 membered heterocyclyl, C6-10 aryl and 5 to 10 membered heteroaryl can be each optionally further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, amino, C1-3 alkyl and 3 to 6 membered heterocyclyl.
In some embodiments of the present invention, Ra1, Ra2 and Ra3 are each independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, cyano, amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl can be each optionally further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, amino, C1-6 alkyl and 3 to 12 membered heterocyclyl.
In some embodiments of the present invention, each Ra is independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, oxo, cyano, amino optionally substituted by C1-3 alkyl, C1-3 haloalkyl, C1-3 alkyl, C1-3 alkoxy, C2-4 alkynyl and C3-6 cycloalkyl.
In some embodiments of the present invention, each Ra is independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, oxo, cyano, amino, C1-3 haloalkyl, C1-3 alkyl and C3-6 cycloalkyl.
In some embodiments of the present invention, each Ra is independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, oxo, cyano, amino, C1-3 alkyl and C3-6 cycloalkyl.
In some embodiments of the present invention, each Ra is independently selected from the group consisting of hydrogen, ethyl, oxo, cyclopropyl, methyl, methoxy, ethynyl, propynyl, trifluoromethyl and cyano.
In some embodiments of the present invention, each Ra is independently selected from the group consisting of hydrogen, ethyl, oxo, cyclopropyl, methyl, methoxy, ethynyl, trifluoromethyl and cyano.
In some embodiments of the present invention, each Ra is independently selected from the group consisting of hydrogen, ethyl, oxo, cyclopropyl, methyl, trifluoromethyl and cyano.
In some embodiments of the present invention, each Ra is independently selected from the group consisting of hydrogen, ethyl, oxo, cyclopropyl and methyl.
In some embodiments of the present invention, x is 1, 2 or 3.
In some embodiments of the present invention, each Rb is independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, oxo, cyano, amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl, 5 to 12 membered heteroaryl, —(CH2)nRb1, —(CH2)nORb1, —(CH2)nC(O)Rb1, —(CH2)nC(O)ORb1, —(CH2)nS(O)mRb1, —(CH2)nNRb2Rb3, —(CH2)nNRb2C(O)ORb3, —(CH2)nNRb2C(O)(CH2)n1Rb3, —(CH2)nNRb2C(O)NRb2Rb3, —(CH2)nC(O)NRb2(CH2)n1Rb3, —OC(Rb1Rb2)n(CH2)n1Rb3 and —(CH2)nNRb2S(O)mRb3, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl can be each optionally further substituted by one or more substituents selected from the group consisting of hydroxy, nitro, thiol, oxo, cyano, halogen, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, amino, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C6-10 aryl, 5 to 10 membered heteroaryl and 3 to 12 membered heterocyclyl.
In some embodiments of the present invention, each Rb is independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, oxo, cyano, amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl, 5 to 12 membered heteroaryl, —(CH2)nRb1, —(CH2)nORb1, —(CH2)nC(O)Rb1, —(CH2)nC(O)ORb1, —(CH2)nS(O)mRb1, —(CH2)nNRb2Rb3, —(CH2)nNRb2C(O)ORb3, —(CH2)nNRb2C(O)(CH2)n1Rb3, —(CH2)nNRb2C(O)NRb2Rb3, —(CH2)nC(O)NRb2(CH2)n1Rb3, —OC(Rb1Rb2)n(CH2)n1Rb3 and —(CH2)nNRb2S(O)mRb3, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl can be each optionally further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, amino, C1-6 alkyl and 3 to 12 membered heterocyclyl.
In some embodiments of the present invention, each Rb is independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, oxo, cyano, amino, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 alkoxy, C2-3 alkenyl, C2-3 alkynyl, C3-6 cycloalkyl, 3 to 6 membered heterocyclyl, C6-10 aryl, 5 to 10 membered heteroaryl, —(CH2)nRb1, —(CH2)nORb1, —(CH2)nC(O)Rb1, —(CH2)nC(O)ORb1, —(CH2)nS(O)mRb1, —(CH2)nNRb2Rb3, —(CH2)nNRb2C(O)ORb3, —(CH2)nNRb2C(O)(CH2)n1Rb3, —(CH2)nNRb2C(O)NRb2Rb3, —(CH2)nC(O)NRb2(CH2)n1Rb3, —OC(Rb1Rb2)n(CH2)n1Rb3 and —(CH2)nNRb2S(O)mRb3, the amino, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 alkoxy, C2-3 alkenyl, C2-3 alkynyl, C3-6 cycloalkyl, 3 to 6 membered heterocyclyl, C6-10 aryl and 5 to 10 membered heteroaryl can be each optionally further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, amino, C1-3 alkyl and 3 to 6 membered heterocyclyl.
In some embodiments of the present invention, Rb1, Rb2 and Rb3 are each independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, cyano, amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl can be each optionally further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, amino, C1-6 alkyl and 3 to 12 membered heterocyclyl.
In some embodiments of the present invention, each Rb is independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, oxo, cyano, amino, C1-3 alkyl, C1-3 haloalkyl and C3-6 cycloalkyl.
In some embodiments of the present invention, each Rb is independently selected from the group consisting of hydrogen, F, —CF3, cyano, methyl and cyclopropyl.
In some embodiments of the present invention, y is 1.
In some embodiments of the present invention, each Rc is independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, oxo, cyano, amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl, 5 to 12 membered heteroaryl, —(CH2)nRc1, —(CH2)nORc1, —(CH2)nC(O)Rc1, —(CH2)nC(O)ORc1, —(CH2)nS(O)mRc1, —(CH2)nNRc2Rc3, —(CH2)nNRc2C(O)ORc3, —(CH2)nNRc2C(O)(CH2)n1Rc3, —(CH2)nNRc2C(O)NRc2Rc3, —(CH2)nC(O)NRc2(CH2)n1Rc3, —OC(Rc1Rc2)n(CH2)n1Rc3 and —(CH2)nNRc2S(O)mRc3, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl can be each optionally further substituted by one or more substituents selected from the group consisting of hydroxy, nitro, thiol, oxo, cyano, halogen, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, amino, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C6-10 aryl, 5 to 10 membered heteroaryl and 3 to 12 membered heterocyclyl.
In some embodiments of the present invention, each Rc is independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, oxo, cyano, amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl, 5 to 12 membered heteroaryl, —(CH2)nRc1, —(CH2)nORc1, —(CH2)nC(O)Rc1, —(CH2)nC(O)ORc1, —(CH2)nS(O)mRc1, —(CH2)nNRc2Rc3, —(CH2)nNRc2C(O)ORc3, —(CH2)nNRc2C(O)(CH2)n1Rc3, —(CH2)nNRc2C(O)NRc2Rc3, —(CH2)nC(O)NRc2(CH2)n1Rc3, —OC(Rc1Rc2)n(CH2)n1Rc3 and —(CH2)nNRc2S(O)mRc3, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl can be each optionally further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, amino, C1-6 alkyl and 3 to 12 membered heterocyclyl.
In some embodiments of the present invention, each Rc is independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, oxo, cyano, amino, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 alkoxy, C2-3 alkenyl, C2-3 alkynyl, C3-6 cycloalkyl, 3 to 6 membered heterocyclyl, C6-10 aryl, 5 to 10 membered heteroaryl, —(CH2)nRc1, —(CH2)nORc1, —(CH2)nC(O)Rc1, —(CH2)nC(O)ORc1, —(CH2)nS(O)mRc1, —(CH2)nNRc2Rc3, —(CH2)nNRc2C(O)ORc3, —(CH2)nNRc2C(O)(CH2)n1Rc3, —(CH2)nNRc2C(O)NRc2Rc3, —(CH2)nC(O)NRc2(CH2)n1Rc3, —OC(Rc1Rc2)n(CH2)n1Rc3 and —(CH2)nNRc2S(O)mRc3, the amino, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 alkoxy, C2-3 alkenyl, C2-3 alkynyl, C3-6 cycloalkyl, 3 to 6 membered heterocyclyl, C6-10 aryl and 5 to 10 membered heteroaryl can be each optionally further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, amino, C1-3 alkyl and 3 to 6 membered heterocyclyl.
In some embodiments of the present invention, Rc1, Rc2 and Rc3 are each independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, cyano, amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl can be each optionally further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, amino, C1-6 alkyl and 3 to 12 membered heterocyclyl.
In some embodiments of the present invention, each Rc is independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, oxo, cyano, amino optionally substituted by C1-3 alkyl, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl and C3-6 cycloalkyl.
In some embodiments of the present invention, each Rc is independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, oxo, cyano, amino, C1-3 alkyl, C1-3 haloalkyl and C3-6 cycloalkyl.
In some embodiments of the present invention, each Rc is independently selected from the group consisting of hydrogen, deuterium, F, chlorine, hydroxy, methyl, methoxy, oxo and cyano.
In some embodiments of the present invention, each Rc is independently selected from the group consisting of hydrogen, deuterium, F, hydroxy, methyl, methoxy, oxo and cyano.
In some embodiments of the present invention, each Rc is independently selected from the group consisting of hydrogen, F, hydroxy, methyl, methoxy, oxo and cyano.
In some embodiments of the present invention, each Rc is independently selected from the group consisting of hydrogen, F, methyl, oxo and cyano.
In some embodiments of the present invention, each Rc is independently selected from the group consisting of hydrogen, F, methyl and oxo.
In some embodiments of the present invention, z is 1 or 2.
In some embodiments of the present invention, each Rd is independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, oxo, cyano, amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl, 5 to 12 membered heteroaryl, —(CH2)nRd1, —(CH2)nORd1, —(CH2)nC(O)Rd1, —(CH2)nC(O)ORd1, —(CH2)nS(O)mRc1, —(CH2)nNRd2Rd3, —(CH2)nNRd2C(O)ORd3, —(CH2)nNRd2C(O)(CH2)n1Rd3, —(CH2)nNRd2C(O)NRd2Rd3, —(CH2)nC(O)NRd2(CH2)n1Rd3, —OC(Rd1Rd2)n(CH2)n1Rd3 and —(CH2)nNRd2S(O)mRd3, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl can be each optionally further substituted by one or more substituents selected from the group consisting of hydroxy, nitro, thiol, oxo, cyano, halogen, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, amino, C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C6-10 aryl, 5 to 10 membered heteroaryl and 3 to 12 membered heterocyclyl.
In some embodiments of the present invention, each Rd is independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, oxo, cyano, amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl, 5 to 12 membered heteroaryl, —(CH2)nRd1, —(CH2)nORd1, —(CH2)nC(O)Rd1, —(CH2)nC(O)ORd1, —(CH2)nS(O)mRc1, —(CH2)nNRd2Rd3, —(CH2)nNRd2C(O)ORd3, —(CH2)nNRd2C(O)(CH2)n1Rd3, —(CH2)nNRd2C(O)NRd2Rd3, —(CH2)nC(O)NRd2(CH2)n1Rd3, —OC(Rd1Rd2)n(CH2)n1Rd3 and —(CH2)nNRd2S(O)mRd3, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl can be each optionally further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, amino, C1-6 alkyl and 3 to 12 membered heterocyclyl.
In some embodiments of the present invention, each Rd is independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, oxo, cyano, amino, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 alkoxy, C2-3 alkenyl, C2-3 alkynyl, C3-6 cycloalkyl, 3 to 6 membered heterocyclyl, C6-10 aryl, 5 to 10 membered heteroaryl, —(CH2)nRd1, —(CH2)nORd1, —(CH2)nC(O)Rd1, —(CH2)nC(O)ORd1, —(CH2)nS(O)mRc1, —(CH2)nNRd2Rd3, —(CH2)nNRd2C(O)ORd3, —(CH2)nNRd2C(O)(CH2)n1Rd3, —(CH2)nNRd2C(O)NRd2Rd3, —(CH2)nC(O)NRd2(CH2)n1Rd3, —OC(Rd1Rd2)n(CH2)n1Rd3 and —(CH2)nNRd2S(O)mRd3, the amino, C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 alkoxy, C2-3 alkenyl, C2-3 alkynyl, C3-6 cycloalkyl, 3 to 6 membered heterocyclyl, C6-10 aryl and 5 to 10 membered heteroaryl can be each optionally further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, amino, C1-3 alkyl and 3 to 6 membered heterocyclyl.
In some embodiments of the present invention, Rd1, Rd2 and Rd3 are each independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, cyano, amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl, the amino, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C3-12 cycloalkyl, 3 to 12 membered heterocyclyl, C6-12 aryl and 5 to 12 membered heteroaryl can be each optionally further substituted by one or more substituents selected from the group consisting of hydroxy, halogen, amino, C1-6 alkyl and 3 to 12 membered heterocyclyl.
In some embodiments of the present invention, each Rd is independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, oxo, cyano, amino optionally substituted by C1-3 alkyl, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl and C3-6 cycloalkyl.
In some embodiments of the present invention, each Rd is independently selected from the group consisting of hydrogen, deuterium, cyclopropyl, isopropyl, cyano, F, Cl, methyl, —CD3, —NHCH3, —NHCD3, methoxy and oxo.
In some embodiments of the present invention, each Rd is independently selected from the group consisting of hydrogen, cyclopropyl, cyano, F, Cl, methyl, —NHCH3, methoxy and oxo.
In some embodiments of the present invention, each Rd is independently selected from the group consisting of hydrogen, cyclopropyl, cyano, F, methyl, —NHCH3, methoxy and oxo.
In some embodiments of the present invention, each Rd is independently selected from the group consisting of hydrogen, deuterium, halogen, nitro, hydroxy, thiol, oxo, cyano, amino, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl and C3-6 cycloalkyl.
In some embodiments of the present invention, each Rd is independently selected from the group consisting of hydrogen, cyclopropyl, cyano, F, methyl, methoxy and oxo.
In some embodiments of the present invention, w is 1 or 2.
In some embodiments of the present invention, w is 1.
In some embodiments of the present invention, the compound of formula (I) is a compound of formula (VII):
In some embodiments of the present invention, M6 is N or C—CN.
In some embodiments of the present invention, the compound of formula (I) is a compound of formula (VI):
In some embodiments of the present invention, M3 is N, CH or CF.
In some embodiments of the present invention, M1 is CH or C.
In some embodiments of the present invention, M1 is CH or CD.
In some embodiments of the present invention, R6, R7, R8 and R9 are each independently hydrogen, methyl, ethyl, methoxy, ethynyl, propynyl or cyclopropyl; or, R6, R7 together with the adjacent carbon atom are bonded to form a cyclopropyl; or, R6, R8 together with the adjacent carbon atom are bonded to form a cyclopropyl.
In some embodiments of the present invention, R6, R7, R8 and R9 are each independently hydrogen, methyl, ethyl, methoxy, ethynyl or cyclopropyl; or, R6, R7 together with the adjacent carbon atom are bonded to form a cyclopropyl; or, R6, R8 together with the adjacent carbon atom are bonded to form a cyclopropyl.
In some embodiments of the present invention, R1 is —NHCH3 or —NH-cyclopropyl.
In some embodiments of the present invention, Rd is hydrogen, fluorine, chlorine or cyclopropyl.
In some embodiments of the present invention, Rd is hydrogen or cyclopropyl.
In some embodiments of the present invention, the compound of formula (I) is a compound of formula (V):
In some embodiments of the present invention, M1 is C or CH.
In some embodiments of the present invention, M2 is CH.
In some embodiments of the present invention, M4 is CH.
In some embodiments of the present invention, M3 is N or CF.
In some embodiments of the present invention, R1 is selected from the group consisting of C1-3 alkyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 hydroxyalkyl, C1-3 alkoxy, —(CH2)nR11, —(CH2)nOR11, —(CH2)nC(O)R11, (CH2)nC(O)OR11, —(CH2)nNR22R33 and —(CH2)nNR22C(O)OR33.
In some embodiments of the present invention, R11, R22 and R33 are each independently selected from the group consisting of hydrogen, deuterium, halogen, amino, hydroxy, cyano, nitro, C1-3 alkyl, C2-3 alkenyl, C2-3 alkynyl, C1-3 deuterated alkyl, C1-3 haloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, C1-3 hydroxyalkyl, C3-6 cycloalkyl, 3 to 6 membered heterocyclyl, C6-10 aryl and 5 to 10 membered heteroaryl.
In some embodiments of the present invention, R1 is —NHCH3,
In some embodiments of the present invention, provided is the compound of formula (V), the stereoisomer thereof or the pharmaceutically acceptable salt thereof, wherein:
In some embodiments of the present invention, the compound is further as shown in formula (IX):
In some embodiments of the present invention, the compound of formula (I) is a compound of formula (VIII):
In formula (VIII), M1 is preferably ═C or —N.
In formula (VIII), M2 is preferably CH.
In formula (VIII), M6 is preferably N or CH.
In formula (VIII), M7 is preferably CH or N.
In formula (VIII), M8 is preferably
CH or —O.
In formula (VIII), Rb is preferably hydrogen, deuterium or F.
In formula (VIII), Rc is preferably hydrogen.
In formula (VIII), Rd is preferably hydrogen, deuterium, F, Cl, methyl, —CD3, —NHCH3.
In formula (VIII), w is preferably 1 or 2.
In formula (VIII), y is preferably 1.
The present invention also provides a method for preparing the compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof, wherein: the compound is as shown in formula (III), a compound of formula (III-1) and a compound of formula (III-2) are subjected to the following reaction,
The present invention also provides a compound of formula (III-2).
The present invention further relates to a pharmaceutical composition comprising a therapeutically effective dose of any one of the compound of formula (I), the stereoisomer thereof or the pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.
The present invention further relates to a use of any one of the compound of formula (I), the stereoisomer thereof or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising the same in the preparation of a PARP inhibitor medicament, wherein the PARP is preferably PARP1.
The present invention further relates to a use of the compound of formula (I), the stereoisomer thereof or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising the same in the preparation of a medicament for treating cancer, ischemic disease, or neurodegenerative disease, wherein the cancer is preferably selected from the group consisting of breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, blood cancer, gastric cancer, colorectal cancer, gastrointestinal cancer and lung cancer.
The present invention further relates to a method for treating cancer, ischemic disease, or neurodegenerative disease by the compound of formula (I), the stereoisomer thereof or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising the same.
The present invention also relates to a method for preventing and/or treating ischemic disease, neurodegenerative disease, breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, blood cancer, gastrointestinal cancer or lung cancer, comprising a step of administering a therapeutically effective dose of the compound of formula (I), the stereoisomer thereof or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising the same to a patient. Preferably, the gastrointestinal cancer is selected from the group consisting of gastric cancer and colorectal cancer.
The present invention also provides a method for treating disease condition by using the compound or the pharmaceutical composition of the present invention, wherein the disease condition includes, but is not limited to, condition associated with PARP kinase dysfunction. The PARP is preferably PARP1 or PARP2.
The present invention also relates to a method for treating cancer in a mammal, comprising a step of administering a therapeutically effective amount of the compound or the pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof of the present invention to the mammal.
In some embodiments of the present invention, the method relates to the treatment of conditions such as cancer, ischemic disease or neurodegenerative disease.
In some embodiments of the present invention, the method relates to the treatment of breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, blood cancer, gastrointestinal cancer or lung cancer; preferably, the gastrointestinal cancer is selected from the group consisting of gastric cancer and colorectal cancer.
In some embodiments of the present invention, the method relates to the treatment of ovarian cancer or breast cancer.
In some embodiments of the present invention, the cancer is breast cancer, ovarian cancer, pancreatic cancer, prostate cancer.
Unless otherwise stated, the terms used in the specification and claims have the meanings described below.
The term “alkyl” refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group comprising 1 to 20 carbon atoms, preferably an alkyl having 1 to 8 carbon atoms, more preferably an alkyl having 1 to 6 carbon atoms, and most preferably an alkyl having 1 to 3 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched isomers thereof. More preferably, the alkyl is a lower alkyl having 1 to 6 carbon atoms, and non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl and the like. The alkyl can be substituted or unsubstituted. When substituted, the substituent(s) can be substituted at any available connection point. The substituent(s) is preferably one or more group(s) independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocyclylthio, oxo, carboxy and alkoxycarbonyl. The alkyl of the present invention is preferably selected from the group consisting of methyl, ethyl, isopropyl, tert-butyl, haloalkyl, deuterated alkyl, alkoxy-substituted alkyl and hydroxy-substituted alkyl.
The term “alkylene” refers to an alkyl of which a hydrogen atom is further substituted, for example, “methylene” refers to —CH2—, “ethylene” refers to —(CH2)2—, “propylene” refers to —(CH2)3—, “butylene” refers to —(CH2)4— and the like. The term “alkenyl” refers to an alkyl as defined above that consists of at least two carbon atoms and at least one carbon-carbon double bond, for example, ethenyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl and the like. The alkenyl can be substituted or unsubstituted. When substituted, the substituent(s) is preferably one or more groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio and heterocyclylthio.
The term “cycloalkyl” refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent group having 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, and more preferably 3 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl and the like. Polycyclic cycloalkyl includes a cycloalkyl having a spiro ring, fused ring or bridged ring. The cycloalkyl is preferably cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl and cycloheptyl.
The term “spiro cycloalkyl” refers to a 5 to 20 membered polycyclic group with individual rings connected through one shared carbon atom (called a spiro atom), wherein the rings can contain one or more double bonds, but none of the rings has a completely conjugated π-electron system. The spiro cycloalkyl is preferably a 6 to 14 membered spiro cycloalkyl, and more preferably a 7 to 10 membered spiro cycloalkyl. According to the number of the spiro atoms shared between the rings, the spiro cycloalkyl can be divided into a mono-spiro cycloalkyl, a di-spiro cycloalkyl, or a poly-spiro cycloalkyl, and the spiro cycloalkyl is preferably a mono-spiro cycloalkyl or di-spiro cycloalkyl, and more preferably a 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered, or 5-membered/6-membered mono-spiro cycloalkyl. Non-limiting examples of spiro cycloalkyl include:
The term “fused cycloalkyl” refers to a 5 to 20 membered all-carbon polycyclic group, wherein each ring in the system shares an adjacent pair of carbon atoms with another ring, one or more rings can contain one or more double bonds, but none of the rings has a completely conjugated π-electron system. The fused cycloalkyl is preferably a 6 to 14 membered fused cycloalkyl, and more preferably a 7 to 10 membered fused cycloalkyl. According to the number of membered rings, the fused cycloalkyl can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl, and the fused cycloalkyl is preferably a bicyclic or tricyclic fused cycloalkyl, and more preferably a 5-membered/5-membered or 5-membered/6-membered bicyclic fused cycloalkyl. Non-limiting examples of fused cycloalkyl include:
The term “bridged cycloalkyl” refers to a 5 to 20 membered all-carbon polycyclic group, wherein every two rings in the system share two disconnected carbon atoms, the rings can have one or more double bonds, but none of the rings has a completely conjugated π-electron system. The bridged cycloalkyl is preferably a 6 to 14 membered bridged cycloalkyl, and more preferably a 7 to 10 membered bridged cycloalkyl. According to the number of membered rings, the bridged cycloalkyl can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl, and the bridged cycloalkyl is preferably a bicyclic, tricyclic or tetracyclic bridged cycloalkyl, and more preferably a bicyclic or tricyclic bridged cycloalkyl. Non-limiting examples of bridged cycloalkyl include:
The cycloalkyl ring can be fused to the ring of aryl, heteroaryl or heterocyclyl, wherein the ring bound to the parent structure is cycloalkyl. Non-limiting examples include indanyl, tetrahydronaphthyl, benzocycloheptyl and the like. The cycloalkyl can be optionally substituted or unsubstituted. When substituted, the substituent(s) is preferably one or more group(s) independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocyclylthio, oxo, carboxy and alkoxycarbonyl.
The term “heterocyclyl” refers to a 3 to 20 membered saturated or partially unsaturated monocyclic or polycyclic hydrocarbon group, wherein one or more ring atoms are heteroatoms selected from the group consisting of nitrogen, oxygen and S(O)m (wherein m is an integer of 0 to 2), but excluding —O—O—, —O—S— or —S—S— in the ring, with the remaining ring atoms being carbon atoms; wherein the ring atom can be further boron or P(O)p (wherein p is an integer of 0 to 2). Preferably, the heterocyclyl has 3 to 12 ring atoms wherein 1 to 4 atoms are heteroatoms; more preferably, 3 to 8 ring atoms; and most preferably 3 to 8 ring atoms. Non-limiting examples of monocyclic heterocyclyl include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, pyranyl and the like, preferably tetrahydrofuryl, pyrazolidinyl, morpholinyl, piperazinyl and pyranyl. Polycyclic heterocyclyl includes a heterocyclyl having a spiro ring, fused ring or bridged ring. The heterocyclyl having a spiro ring, fused ring or bridged ring is optionally bonded to other group via a single bond, or further bonded to other cycloalkyl, heterocyclyl, aryl and heteroaryl via any two or more atoms on the ring.
Non-limiting examples of heterocyclyl include
The term “spiro heterocyclyl” refers to a 5 to 20 membered polycyclic heterocyclyl group with individual rings connected through one shared atom (called a spiro atom), wherein one or more ring atoms are heteroatoms selected from the group consisting of nitrogen, oxygen and S(O)m (wherein m is an integer of 0 to 2), with the remaining ring atoms being carbon atoms, and the rings can contain one or more double bonds, but none of the rings has a completely conjugated π-electron system. The spiro heterocyclyl is preferably a 6 to 14 membered spiro heterocyclyl, and more preferably a 7 to 10 membered spiro heterocyclyl. According to the number of the spiro atoms shared between the rings, the spiro heterocyclyl can be divided into a mono-spiro heterocyclyl, di-spiro heterocyclyl, or poly-spiro heterocyclyl, and the spiro heterocyclyl is preferably a mono-spiro heterocyclyl or di-spiro heterocyclyl, and more preferably a 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered, or 5-membered/6-membered mono-spiro heterocyclyl. Non-limiting examples of spiro heterocyclyl include:
The term “fused heterocyclyl” refers to a 5 to 20 membered polycyclic heterocyclyl group, wherein each ring in the system shares an adjacent pair of atoms with another ring, one or more rings can contain one or more double bonds, but none of the rings has a completely conjugated π-electron system, and one or more ring atoms are heteroatoms selected from the group consisting of nitrogen, oxygen and S(O)m (wherein m is an integer of 0 to 2), with the remaining ring atoms being carbon atoms. The fused heterocyclyl is preferably a 6 to 14 membered fused heterocyclyl, and more preferably a 7 to 10 membered fused heterocyclyl. According to the number of membered rings, the fused heterocyclyl can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclyl, and preferably a bicyclic or tricyclic fused heterocyclyl, and more preferably a 5-membered/5-membered or 5-membered/6-membered bicyclic fused heterocyclyl. Non-limiting examples of fused heterocyclyl include:
The term “bridged heterocyclyl” refers to a 5 to 14 membered polycyclic heterocyclyl group, wherein every two rings in the system share two disconnected atoms, wherein the rings can have one or more double bond(s), but none of the rings has a completely conjugated π-electron system, and one or more ring atoms are heteroatoms selected from the group consisting of nitrogen, oxygen and S(O)m (wherein m is an integer of 0 to 2), with the remaining ring atoms being carbon atoms. The bridged heterocyclyl is preferably a 6 to 14 membered bridged heterocyclyl, and more preferably a 7 to 10 membered bridged heterocyclyl. According to the number of membered rings, the bridged heterocyclyl can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclyl, and the bridged heterocyclyl is preferably a bicyclic, tricyclic or tetracyclic bridged heterocyclyl, and more preferably a bicyclic or tricyclic bridged heterocyclyl. Non-limiting examples of bridged heterocyclyl include:
The heterocyclyl ring can be fused to the ring of aryl, heteroaryl or cycloalkyl, wherein the ring bound to the parent structure is heterocyclyl. Non-limiting examples include:
and the like.
The heterocyclyl can be optionally substituted or unsubstituted. When substituted, the substituent(s) is preferably one or more group(s) independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocyclylthio, oxo, carboxy and alkoxycarbonyl.
The term “aryl” refers to a 6 to 14 membered all-carbon monocyclic ring or polycyclic fused ring (i.e. each ring in the system shares an adjacent pair of carbon atoms with another ring in the system) having a conjugated π-electron system, preferably a 6 to 10 membered aryl, for example, phenyl and naphthyl. The aryl is more preferably phenyl. The aryl ring can be fused to the ring of heteroaryl, heterocyclyl or cycloalkyl, wherein the ring bound to the parent structure is aryl ring. Non-limiting examples include:
The aryl can be substituted or unsubstituted. When substituted, the substituent(s) is preferably one or more group(s) independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocyclylthio, carboxy and alkoxycarbonyl.
The term “heteroaryl” refers to a 5 to 14 membered heteroaromatic system having 1 to 4 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen. The heteroaryl is preferably a 5 to 10 membered heteroaryl, and more preferably a 5 or 6 membered heteroaryl, for example imidazolyl, furanyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazolyl, pyrazinyl and the like, preferably triazolyl, thienyl, imidazolyl, pyrazolyl or pyrimidinyl, thiazolyl, and more preferably triazolyl, pyrrolyl, thienyl, thiazolyl and pyrimidinyl. The heteroaryl ring can be fused to the ring of aryl, heterocyclyl or cycloalkyl, wherein the ring bound to the parent structure is heteroaryl ring. Non-limiting examples thereof include:
The heteroaryl can be optionally substituted or unsubstituted. When substituted, the substituent(s) is preferably one or more group(s) independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocyclylthio, carboxy and alkoxycarbonyl.
The term “alkoxy” refers to an —O-(alkyl) or an —O-(unsubstituted cycloalkyl) group, wherein the alkyl is as defined above. Non-limiting examples of alkoxy include methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy. The alkoxy can be optionally substituted or unsubstituted. When substituted, the substituent(s) is preferably one or more group(s) independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocyclylthio, carboxy and alkoxycarbonyl.
“Haloalkyl” refers to an alkyl substituted by one or more halogen(s), wherein the alkyl is as defined above.
“Haloalkoxy” refers to an alkoxy substituted by one or more halogen(s), wherein the alkoxy is as defined above.
“Hydroxyalkyl” refers to an alkyl substituted by hydroxy(s), wherein the alkyl is as defined above.
“Alkenyl” refers to a chain olefin, also known as alkene group. The alkenyl can be further substituted by other related group, for example alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocyclylthio, carboxy or alkoxycarbonyl.
“Alkynyl” refers to (CH≡C—). The alkynyl can be further substituted by other related group, for example alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocyclylthio, carboxy or alkoxycarbonyl.
“Hydroxy” refers to an —OH group.
“Halogen” refers to fluorine, chlorine, bromine or iodine.
“Amino” refers to a —NH2 group.
“Cyano” refers to a —CN group.
“Nitro” refers to a —NO2 group.
“Carboxy” refers to a —C(O)OH group.
“THF” refers to tetrahydrofuran.
“EtOAc” refers to ethyl acetate.
“MeOH” refers to methanol.
“DMF” refers to N,N-dimethylformamide.
“DIPEA” refers to diisopropylethylamine.
“TFA” refers to trifluoroacetic acid.
“MeCN” refers to acetonitrile.
“DMA” refers to N,N-dimethylacetamide.
“Et2O” refers to diethyl ether.
“DCE” refers to 1,2-dichloroethane.
“DIPEA” refers to N,N-diisopropylethylamine.
“NBS” refers to N-bromosuccinimide.
“NIS” refers to N-iodosuccinimide.
“Cbz-Cl” refers to benzyl chloroformate.
“Pd2(dba)3” refers to tris(dibenzylideneacetone)dipalladium.
“Dppf” refers to 1,1′-bisdiphenylphosphinoferrocene.
“HATU” refers to 2-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate.
“KHMDS” refers to potassium hexamethyldisilazide.
“LiHMDS” refers to lithium bis(trimethylsilyl)amide.
“MeLi” refers to methyl lithium.
“n-BuLi” refers to n-butyl lithium.
“NaBH(OAc)3” refers to sodium triacetoxyborohydride.
Different expressions such as “X is selected from the group consisting of A, B or C”, “X is selected from the group consisting of A, B and C”, “X is A, B or C”, “X is A, B and C” are the same meaning, that is, X can be any one or more of A, B and C.
The hydrogen atom of the present invention can be replaced by its isotope deuterium. Any of the hydrogen atoms in the compounds of the examples of the present invention can also be substituted by deuterium atom.
“Optional” or “optionally” means that the event or circumstance described subsequently can, but need not, occur, and such a description includes the situation in which the event or circumstance does or does not occur. For example, “the heterocyclyl optionally substituted by an alkyl” means that an alkyl group can be, but need not be, present, and such a description includes the situation of the heterocyclyl being substituted by an alkyl and the heterocyclyl being not substituted by an alkyl.
“Substituted” refers to one or more hydrogen atoms in a group, preferably up to 5, and more preferably 1 to 3 hydrogen atoms, independently substituted by a corresponding number of substituents. It goes without saying that the substituents only exist in their possible chemical position. The person skilled in the art is able to determine whether the substitution is possible or impossible by experiments or theory without excessive efforts. For example, the combination of amino or hydroxy having free hydrogen and carbon atoms having unsaturated bonds (such as olefinic) may be unstable.
A “pharmaceutical composition” refers to a mixture of one or more of the compounds according to the present invention or physiologically/pharmaceutically acceptable salts or prodrugs thereof with other chemical components such as physiologically/pharmaceutically acceptable carriers and excipients. The purpose of the pharmaceutical composition is to facilitate administration of a compound to an organism, which is conducive to the absorption of the active ingredient so as to exert biological activity.
A “pharmaceutically acceptable salt” refers to a salt of the compound of the present invention, which is safe and effective in mammals and has the desired biological activity.
The present invention will be further described with reference to the following examples, but the examples should not be considered as limiting the scope of the present invention.
The structures of the compounds of the present invention were identified by nuclear magnetic resonance (NMR) and/or liquid chromatography-mass spectrometry (LC-MS). NMR shifts (δ) are given in parts per million (ppm). NMR is determined by a Bruker AVANCE-400 instrument. The solvents for determination are deuterated-dimethyl sulfoxide (DMSO-d6), deuterated-methanol (CD3OD) and deuterated-chloroform (CDCl3), and the internal standard is tetramethylsilane (TMS).
Liquid chromatography-mass spectrometry (LC-MS) was determined on an Agilent 1200 Infinity Series mass spectrometer. High performance liquid chromatography (HPLC) was determined on an Agilent 1200DAD high pressure liquid chromatograph (Sunfire C18 150×4.6 mm column), and a Waters 2695-2996 high pressure liquid chromatograph (Gimini C18 150×4.6 mm column).
Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate was used as the thin-layer silica gel chromatography (TLC) plate. The dimension of the silica gel plate used in TLC is 0.15 mm to 0.2 mm, and the dimension of the silica gel plate used in product purification is 0.4 mm to 0.5 mm. Yantai Huanghai 200 to 300 mesh silica gel was generally used as a carrier for column chromatography.
The raw materials used in the examples of the present invention are known and commercially available, or can be synthesized by or according to known methods in the art.
Unless otherwise stated, all reactions of the present invention are carried out under continuous magnetic stirring under a dry nitrogen or argon atmosphere. The solvent is dry, and the reaction temperature is in degrees celsius.
Selenium dioxide (3.96 g, 35.68 mmol) was added to a solution of ethyl 6-methyl-5-nitronicotinate (5.0 g, 23.8 mmol) in 1,4-dioxane (25 mL). The reaction solution was heated to 110° C. and stirred for 20 hours. The reaction solution was cooled to room temperature, and filtered through diatomaceous earth under reduced pressure. The filtrate was concentrated under reduced pressure to remove the organic solvent, and the resulting residue was purified by column chromatography to obtain the brown oily compound ethyl 6-formyl-5-nitronicotinate (4.8 g, 90%).
MS m/z (ES+): 224.1 [M]+.
In an ice bath, triethyl 2-phosphonobutyrate (12.8 g, 50.6 mmol) was slowly added dropwise to a solution of NaH (60 wt %, 2.0 g, 50.6 mmol) in tetrahydrofuran (30 mL). The reaction solution was stirred in the ice bath for 0.5 hours, then warmed up to room temperature and stirred for 0.5 hours, then heated to 40° C. and stirred for 10 minutes. The reaction solution was cooled to −78° C., and a solution of ethyl 6-formyl-5-nitronicotinate (4.8 g, 21 mmol) in tetrahydrofuran (20 mL) was slowly added dropwise, and stirred at −78° C. for 1 hour. The reaction solution was quenched with saturated aqueous ammonium chloride, and extracted three times with ethyl acetate. The organic phases were combined, and washed with saturated brine. The organic phase was separated, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to remove the organic solvent, and the resulting residue was purified by column chromatography to obtain the title compound ethyl (E)-6-(2-(ethoxycarbonyl)but-1-en-1-yl)-5-nitronicotinate (5.1 g, 75%).
MS m/z (ES+): 322.2 [M]+.
Palladium on carbon (1.86 g, 1.76 mmol) was added to a solution of ethyl (E)-6-(2-(ethoxycarbonyl)but-1-en-1-yl)-5-nitronicotinate (3.76 g, 11.6 mmol) in ethanol (50 mL). The reaction solution was purged with nitrogen for five minutes, placed under a hydrogen atmosphere, and stirred overnight at room temperature. The reaction solution was filtered through diatomaceous earth under reduced pressure. The filtrate was concentrated under reduced pressure to obtain the crude product ethyl 7-ethyl-6-oxo-5,6,7,8-tetrahydro-1,5-naphthyridine-3-carboxylate (2.8 g), which was used directly in the next step.
MS m/z (ESI): 249.2 [M+H]+.
DDQ (2.85 g, 12.5 mmol) was added to a solution of ethyl 7-ethyl-6-oxo-5,6,7,8-tetrahydro-1,5-naphthyridine-3-carboxylate (2.8 g, 11.3 mmol) in 1,4-dioxane (50 mL), heated to 110° C. and stirred for 4 hours. The reaction solution was cooled to room temperature, and filtered through diatomaceous earth under reduced pressure. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by column chromatography to obtain the compound ethyl 7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridine-3-carboxylate (2.1 g, 76%).
MS m/z (ESI): 247.2 [M+H]+.
In an ice bath, a solution of lithium aluminum hydride in THF (2 M, 8.5 mL, 17.0 mmol) was slowly added to a solution of 7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridine-3-carboxylate (2.1 g, 8.5 mmol) in THE (30 mL), and stirred under the ice bath for 2 hours. The reaction solution was quenched with sodium sulfate decahydrate, and filtered through diatomaceous earth under reduced pressure. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by column chromatography to obtain the compound 3-ethyl-7-(hydroxymethyl)-1,5-naphthyridin-2(1H)-one (1.5 g, 86%).
MS m/z (ESI): 205.2 [M+H]+.
In an ice bath, thionyl chloride (3.2 mL, 44.1 mmol) was added to a solution of 3-ethyl-7-(hydroxymethyl)-1,5-naphthyridin-2(1H)-one (1.5 g, 7.4 mmol) in dichloromethane (30 mL). DMF (0.06 mL, 0.77 mmol) was added, and the reaction solution was stirred at room temperature for 6 hours. The reaction solution was concentrated under reduced pressure to remove the organic solvent, so as to obtain the crude product 7-(chloromethyl)-3-ethyl-1,5-naphthyridin-2(1H)-one (1.61 g), which was used directly in the next step.
MS m/z (ESI): 223.1 [M+H]+.
At room temperature, methyl 5-bromopicolinate (1.0 g, 4.6 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (1.6 g, 5.1 mmol), 1,1′-bis(diphenylphosphino)ferrocene palladium(II)dichloride (146 mg, 0.2 mmol) and potassium carbonate (1.6 g, 11.6 mmol) were dissolved in N,N-dimethylformamide (10 mL). The reaction solution was purged with nitrogen for 1 minute, heated to 140° C. and reacted under microwave for 30 minutes. Water was added to the reaction system, and extracted with ethyl acetate. The organic phase was separated, washed with saturated brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to remove the organic solvent, and the resulting residue was purified by column chromatography to obtain the brown oily compound 1′-(tert-butyl) 6-methyl 3′,6′-dihydro-[3,4′-bipyridine]-1′,6(2′H)-dicarboxylate (620 mg, 42%).
MS m/z (ES+): 319.1 [M+H]+.
At room temperature, a solution of methylamine in alcohol (30 wt %, 2.0 g, 19.5 mmol) was added to a solution of 1′-(tert-butyl) 6-methyl 3′,6′-dihydro-[3,4′-bipyridine]-1′,6(2′H)-dicarboxylate (620 mg, 1.9 mmol) in methanol (8 mL), and stirred at room temperature for 4 hours. The reaction solution was concentrated under reduced pressure, saturated aqueous ammonium chloride solution was added and extracted three times with DCM. The organic phases were combined, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to remove the organic solvent, so as to obtain the crude product tert-butyl 6-(methylcarbamoyl)-3′,6′-dihydro-[3,4′-bipyridine]-1′(2′H)-carboxylate (600 mg), which was used directly in the next step without further purification.
MS m/z (ESI): 318.2 [M+H]+.
In an ice bath, trifluoroacetic acid (1 mL) was added to a solution of tert-butyl 6-(methylcarbamoyl)-3′,6′-dihydro-[3,4′-bipyridine]-1′(2′H)-carboxylate (200 mg, 0.6 mmol) in dichloromethane (5 mL), and stirred at room temperature for 4 hours. The reaction solution was concentrated under reduced pressure to remove the organic solvent, so as to obtain the crude product N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide (155 mg), which was used directly in the next step without further purification.
MS m/z (ESI): 218.2 [M+H]+.
DIPEA (58 mg, 0.45 mmol) and potassium iodide (3 mg, 0.02 mmol) were added to a solution of 7-(chloromethyl)-3-ethyl-1,5-naphthyridin-2(1H)-one (20 mg, 0.09 mmol) and N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide (52 mg, 0.24 mmol) in acetonitrile (3 mL). The reaction solution was heated to 80° C. and stirred for 2 hours. The reaction solution was cooled to room temperature, and filtered under reduced pressure. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by column chromatography to obtain the compound 1′-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide (6.2 mg, 17%).
1H NMR (400 MHz, DMSO-d6) δ 11.76-11.91 (m, 1H), 8.68-8.73 (m, 2H), 8.40-8.44 (m, 1H), 8.02-7.95 (m, 2H), 7.76 (s, 1H), 7.65 (s, 1H), 6.41-6.44 (m, 1H), 3.69-3.76 (m, 2H), 3.19-3.13 (m, 2H), 2.77-2.85 (m, 3H), 2.66-2.74 (m, 2H), 2.51-2.59 (m, 4H), 1.18 (t, J=7.4 Hz, 3H); MS m/z (ESI): 404.2 [M+H]+.
Under a nitrogen atmosphere, Pd/C (50 mg) was added to a solution of tert-butyl 6-(methylcarbamoyl)-3′,6′-dihydro-[3,4′-bipyridine]-1′(2′H)-carboxylate (400 mg, 1.3 mmol) in methanol (8 mL). The reaction solution was purged with hydrogen three times, and stirred at room temperature for 16 hours. The reaction solution was filtered, concentrated under reduced pressure to remove the organic solvent, so as to obtain the crude product tert-butyl 4-(6-(methylcarbamoyl)pyridin-3-yl)piperidine-1-carboxylate (280 mg), which was used directly in the next step without further purification.
MS m/z (ESI): 320.2 [M+H]+.
In an ice bath, hydrochloride acid in dioxane (2 mL) was added to a solution of tert-butyl 4-(6-(methylcarbamoyl)pyridin-3-yl)piperidine-1-carboxylate (280 mg, 0.88 mmol) in dichloromethane (5 mL), and stirred at room temperature for 4 hours. The reaction solution was concentrated under reduced pressure to remove the organic solvent, so as to obtain the crude product N-methyl-5-(piperidin-4-yl)picolinamide (230 mg), which was used directly in the next step without further purification.
MS m/z (ESI): 220.2 [M+H]+.
DIPEA (58 mg, 0.45 mmol) and potassium iodide (3 mg, 0.02 mmol) were added to a solution of 7-(chloromethyl)-3-ethyl-1,5-naphthyridin-2(1H)-one (20 mg, 0.09 mmol) and N-methyl-5-(piperidin-4-yl)picolinamide (52 mg, 0.24 mmol) in acetonitrile (3 mL). The reaction solution was heated to 80° C. and stirred for 2 hours. The reaction solution was cooled to room temperature, and filtered under reduced pressure. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by column chromatography to obtain the compound 5-(1-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperidin-4-yl)-N-methylpicolinamide (6.5 mg, 18%).
1H NMR (400 MHz, DMSO-d6) δ 11.79-11.87 (m, 1H), 8.66-8.72 (m, 1H), 8.53 (s, 1H), 8.38-8.42 (m, 1H), 7.92-7.97 (m, 1H), 7.84-7.88 (m, 1H), 7.75 (s, 1H), 7.61 (s, 1H), 3.58-3.65 (m, 2H), 2.91-2.97 (m, 2H), 2.77-2.84 (m, 3H), 2.63-2.72 (m, 1H), 2.51-2.58 (m, 2H), 2.08-2.17 (m, 2H), 1.67-1.84 (m, 4H), 1.18 (t, J=7.4 Hz, 3H);
MS m/z (ESI): 406.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(8-(methylamino)-1,7-naphthyridin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 1.
It can also be synthesized according to the following steps:
3-Bromo-8-chloro-1,7-naphthyridine (1 g, 4.10 mmol), tert-butyl piperazine-1-carboxylate (918 mg, 4.93 mmol), 1,1′-bis(diphenylphosphino)ferrocene palladium(II)dichloride (146 mg, 0.20 mmol) and potassium carbonate (1.61 g, 11.65 mmol) were mixed in DMF (10 mL), warmed up to 100° C. and reacted for 12 hours. The reaction solution was cooled to room temperature, diluted with water (100 mL), and extracted with ethyl acetate (100 mL×3). The organic phases were combined, washed with saturated sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography to obtain the target compound tert-butyl 4-(8-chloro-1,7-naphthyridin-3-yl)piperazine-1-carboxylate (510 mg, 35.7%).
MS m/z (ESI): 349.1 [M+H]+.
A solution of methylamine in alcohol (30 wt %, 2.0 g, 19.5 mmol) was added to a solution of tert-butyl 4-(8-chloro-1,7-naphthyridin-3-yl)piperazine-1-carboxylate (510 mg, 1.46 mmol) in methanol (8 mL), warmed up to 80° C. and stirred for 12 hours. The reaction solution was concentrated under reduced pressure, and partitioned between DCM and water. The organic phase was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to remove the organic solvent, so as to obtain the crude target compound tert-butyl 4-(8-(methylamino)-1,7-naphthyridin-3-yl)piperazine-1-carboxylate (500 mg), which was used directly in the next step.
MS m/z (ESI): 344.2 [M+H]+.
In an ice bath, trifluoroacetic acid (1 mL) was added to a solution of tert-butyl 4-(8-(methylamino)-1,7-naphthyridin-3-yl)piperazine-1-carboxylate (200 mg, 0.58 mmol) in dichloromethane (5 mL), and stirred at room temperature for 4 hours. The reaction solution was concentrated under reduced pressure to obtain the crude target compound N-methyl-3-(piperazin-1-yl)-1,7-naphthyridin-8-amine (140 mg), which was used directly in the next step.
MS m/z (ESI): 244.2 [M+H]+.
DIPEA (52 mg, 0.41 mmol) and potassium iodide (3 mg, 0.02 mmol) were added to a solution of 7-(chloromethyl)-3-ethyl-1,5-naphthyridin-2(1H)-one (30 mg, 0.13 mmol) and N-methyl-3-(piperazin-1-yl)-1,7-naphthyridin-8-amine (49 mg, 0.20 mmol) in acetonitrile (3 mL). The reaction solution was heated to 80° C. and reacted for 3 hours. The reaction solution was cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by column chromatography to obtain the target compound 3-ethyl-7-((4-(8-(methylamino)-1,7-naphthyridin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one (12 mg, 21.5%).
1H NMR (400 MHz, DMSO-d6) δ 11.76 (s, 1H), 8.33 (s, 1H), 7.65-7.70 (s, 2H), 7.55 (s, 1H), 7.52-7.76 (m, 1H), 6.64-6.73 (m, 2H), 3.57 (s, 2H), 3.32-3.35 (m, 4H), 2.68 (d, J=4.4 Hz, 3H), 2.47-2.51 (m, 6H), 1.11 (t, J=7.4 Hz, 3H);
MS m/z (ESI): 430.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(2-methyl-1-oxo-1,2-dihydroisoquinolin-6-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 430.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(2-methyl-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 432.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(2-methyl-1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 418.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(2-methyl-1-oxo-1,2-dihydrophthalazin-6-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 431.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(8-(methylamino)quinolin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
1H NMR (400 MHz, DMSO-d6) δ 11.86 (s, 1H), 8.64 (d, J=2.7 Hz, 1H), 8.43 (d, J=1.5 Hz, 1H), 7.76 (s, 1H), 7.65 (s, 1H), 7.40 (d, J=2.7 Hz, 1H), 7.23-7.27 (m, 1H), 6.88 (d, J=7.8 Hz, 1H), 6.35-6.40 (m, 2H), 3.64-3.68 (m, 2H), 3.28-3.31 (m, 4H), 2.87 (d, J=5.1 Hz, 3H), 2.58-2.62 (m, 4H), 2.53-2.59 (m, 2H), 1.19 (t, J=7.4 Hz, 3H);
MS m/z (ESI): 429.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(8-(methylamino)-1,5-naphthyridin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 430.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(8-(methylamino)-1,6-naphthyridin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 430.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(4-(methylamino)pyrido[3,2-d]pyrimidin-7-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 431.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(4-(methylamino)pyrido[3,2-c]pyridazin-7-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 431.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(8-(methylamino)pyrido[2,3-d]pyridazin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 431.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(3-(methylamino)isothiazolo[4,5-b]pyridin-6-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 436.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(2-fluoro-3-(methylamino)thieno[3,2-b]pyridin-6-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 453.2 [M+H]+.
The preparation method of 1′-((3-ethyl-2-oxo-1,2,3,4-tetrahydropyrido[3,2-d]pyrimidin-7-yl)methyl)-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 407.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(1-oxoisoindolin-5-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 404.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(1-oxo-1,2-dihydroisoquinolin-6-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 416.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 418.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(1-oxo-1,2-dihydrophthalazin-6-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2 (1H)-one refered to Example 3.
MS m/z (ESI): 417.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 405.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(2-oxoindolin-6-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 404.2 [M+H]+.
The preparation method of 7-((4-(1H-pyrrolo[2,3-b]pyridin-5-yl)piperazin-1-yl)methyl)-3-ethyl-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 389.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(2-methyl-1H-benzo[d]imidazol-6-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
1H NMR (400 MHz, DMSO-d6) δ 11.83-11.90 (br s, 2H), 8.41 (s, 1H), 7.76 (s, 1H), 7.64 (s, 1H), 7.28 (d, J=8.0 Hz, 1H), 6.89 (s, 1H), 6.83 (d, J=8.0 Hz, 1H), 3.65 (s, 2H), 3.06-3.10 (m, 4H), 2.50-2.59 (m, 6H), 2.42 (s, 3H), 1.18 (t, J=8.0 Hz, 3H);
MS m/z (ESI): 403.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(3-(methylamino)pyrazolo[1,5-a]pyrimidin-6-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 419.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(8-(methylamino)pyrrolo[1,2-a]pyrimidin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 418.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(8-(methylamino)imidazo[1,5-a]pyrimidin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 419.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(7-(methylamino)imidazo[1,5-b]pyridazin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 419.2 [M+H]+.
The preparation method of N-cyclopropyl-1′-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
1H NMR (400 MHz, DMSO-d6) δ 11.77 (s, 1H), 8.60 (d, J=4.2 Hz, 2H), 8.30-8.43 (m, 1H), 7.85-8.01 (m, 2H), 7.69 (s, 1H), 7.58 (s, 1H), 6.34 (s, 1H), 3.65 (s, 2H), 3.09 (d, J=3.5 Hz, 2H), 2.83 (q, J=6.4, 5.2 Hz, 1H), 2.63 (t, J=5.5 Hz, 2H), 2.48 (t, J=7.2 Hz, 4H), 1.13 (q, J=9.3, 7.4 Hz, 3H), 0.54-0.72 (m, 4H);
MS m/z (ESI): 430.2 [M+H]+.
The preparation method of 1′-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-N-methoxy-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
1H NMR (400 MHz, DMSO-d6) δ 11.92 (s, 1H), 11.78 (s, 1H), 8.61 (d, J=2.2 Hz, 1H), 8.35 (d, J=1.9 Hz, 1H), 7.94 (dd, J=8.4, 2.3 Hz, 1H), 7.87 (d, J=8.3 Hz, 1H), 7.69 (s, 1H), 7.58 (s, 1H), 6.36 (s, 1H), 3.64 (d, J=13.4 Hz, 5H), 3.09 (d, J=3.4 Hz, 2H), 2.64 (t, J=5.6 Hz, 2H), 2.48 (d, J=7.5 Hz, 4H), 1.12 (t, J=7.4 Hz, 3H);
MS m/z (ESI): 420.2 [M+H]+.
The preparation method of (S)-1′-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-N-(tetrahydrofuran-3-yl)-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 460.2 [M+H]+.
The preparation method of (R)-1′-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-N-(tetrahydrofuran-3-yl)-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 460.2 [M+H]+.
The preparation method of 4-(1-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1,2,3,6-tetrahydropyridin-4-yl)-2-fluoro-N-methylbenzamide refered to Example 1.
1H NMR (400 MHz, DMSO-d6) δ 11.80-11.89 (m, 1H), 8.38-8.45 (m, 1H), 8.13-8.21 (m, 1H), 7.75 (s, 1H), 7.57-7.67 (m, 2H), 7.31-7.38 (m, 2H), 6.33-6.39 (m, 1H), 3.71 (s, 2H), 3.10-3.17 (m, 2H), 2.74-2.81 (m, 3H), 2.65-2.71 (m, 2H), 2.50-2.60 (m, 4H), 1.18 (t, J=7.4 Hz, 3H);
MS m/z (ESI): 421.2 [M+H]+.
The preparation method of 1′-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-2-methoxy-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 434.2 [M+H]+.
The preparation method of 2-cyano-1′-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
1H NMR (400 MHz, DMSO-d6) δ 11.78 (s, 1H), 8.74 (q, J=4.8 Hz, 1H), 8.36 (d, J=1.8 Hz, 1H), 8.04-8.21 (m, 2H), 7.69 (s, 1H), 7.59 (d, J=1.9 Hz, 1H), 6.17 (d, J=4.1 Hz, 1H), 3.68 (s, 2H), 3.12 (d, J=3.3 Hz, 2H), 2.76 (d, J=4.8 Hz, 3H), 2.66 (t, J=5.5 Hz, 2H), 2.48 (d, J=7.0 Hz, 4H), 1.12 (t, J=7.4 Hz, 3H);
MS m/z (ESI): 429.2 [M+H]+.
The preparation method 1′-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-2-fluoro-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
1H NMR (400 MHz, DMSO-d6) δ 11.78 (s, 1H), 8.57 (d, J=5.0 Hz, 1H), 8.35 (d, J=1.8 Hz, 1H), 8.02 (dd, J=9.9, 7.7 Hz, 1H), 7.81-7.90 (m, 1H), 7.69 (s, 1H), 7.58 (s, 1H), 6.19 (s, 1H), 3.65 (s, 2H), 3.10 (s, 2H), 2.72 (d, J=4.8 Hz, 3H), 2.62 (t, J=5.6 Hz, 2H), 2.48 (dd, J=10.3, 4.7 Hz, 4H), 1.12 (t, J=7.4 Hz, 3H);
MS m/z (ESI): 422.2 [M+H]+.
The preparation method of N-methyl-1′-((2′-oxo-1′,4′-dihydro-2′H-spiro[cyclopropane-1,3′-quinolin]-7′-yl)methyl)-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 403.2 [M+H]+.
The preparation method of N-methyl-1′-((2′-oxo-1′,4′-dihydro-2′H-spiro[cyclopropane-1,3′-[1,5]naphthyridin]-7′-yl) methyl)-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 404.2 [M+H]+.
The preparation method of (R)—N-methyl-1′-((3-methyl-2-oxo-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-6-yl)methyl)-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 378.2 [M+H]+.
The preparation method of (S)—N-methyl-1′-((3-methyl-2-oxo-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-6-yl)methyl)-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 378.2 [M+H]+.
The preparation method of 2-cyclopropyl-1′-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 444.2 [M+H]+.
The preparation method of 1′-((5-cyano-3-ethyl-2-oxo-1,2-dihydroquinolin-7-yl)methyl)-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
1H NMR (400 MHz, DMSO-d6) δ 12.10 (s, 1H), 8.66-8.70 (m, 2H), 7.96-8.04 (m, 2H), 7.76 (s, 1H), 7.68 (s, 1H), 7.62 (m, 1H), 6.43 (s, 1H), 3.72 (s, 2H), 3.16 (s, 2H), 2.78-2.82 (m, 3H), 2.66-2.74 (m, 2H), 2.55-2.62 (m, 4H), 1.19 (t, J=7.6 Hz, 3H);
MS m/z (ESI): 428.2 [M+H]+.
The preparation method of 1′-((3-ethyl-5-fluoro-2-oxo-1,2-dihydroquinolin-7-yl)methyl)-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 421.2 [M+H]+.
The preparation method of 1′-((3-ethyl-2-oxo-5-(trifluoromethyl)-1,2-dihydroquinolin-7-yl)methyl)-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 471.2 [M+H]+.
The preparation method of 1′-((7-cyclopropyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
1H NMR (400 MHz, DMSO-d6) δ 11.83-11.91 (m, 1H), 8.67-8.73 (m, 2H), 8.38-8.41 (m, 1H), 7.95-8.02 (m, 2H), 7.60-7.64 (m, 1H), 7.42 (s, 1H), 6.39-6.45 (m, 1H), 3.71 (s, 2H), 3.12-3.19 (m, 2H), 2.78-2.86 (m, 3H), 2.68-2.74 (m, 2H), 2.53-2.59 (m, 2H), 2.10-2.19 (m, 1H), 0.94-1.00 (m, 2H), 0.80-0.85 (m, 2H);
MS m/z (ESI): 416.2 [M+H]+.
The preparation method of 5-(1-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1,2,3,6-tetrahydropyridin-4-yl)-N-methylthiazole-2-carboxamide refered to Example 1.
MS m/z (ESI): 410.2 [M+H]+.
The preparation method of 1′-((3-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[3,2-d]pyrimidin-7-yl)methyl)-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 421.2 [M+H]+.
The preparation method of 1′-((3-ethyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-7-yl)methyl)-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 420.2 [M+H]+.
The preparation method of 1′-((7-ethynyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-N-methyl-1′,2′,3′,6′-tetra hydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 400.2 [M+H]+.
The preparation method of 3-(1-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1,2,3,6-tetrahydropyridin-4-yl)-4-methoxy-N,1-dimethyl-1H-pyrazole-5-carboxamide refered to Example 1.
MS m/z (ESI): 437.2 [M+H]+.
The preparation method of 4-(1-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1,2,3,6-tetrahydropyridin-4-yl)-N,1-dimethyl-1H-imidazole-2-carboxamide refered to Example 1.
MS m/z (ESI): 407.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(8-(methylamino)imidazo[1,2-a]pyrazin-2-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 1.
MS m/z (ESI): 416.2 [M+H]+.
The preparation method of 7-((4-(1,5-dimethyl-1H-imidazol-2-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-3-ethyl-1,5-naphthyridin-2(1H)-one refered to Example 1.
1H NMR (400 MHz, DMSO-d6) δ 11.84 (s, 1H), 8.41 (s, 1H), 7.75 (s, 1H), 7.65 (s, 1H), 6.62 (t, J=0.9 Hz, 1H), 5.93 (s, 1H), 3.70 (d, J=2.7 Hz, 2H), 3.50 (s, 3H), 3.13 (t, J=3.3 Hz, 2H), 2.62 (t, J=5.5 Hz, 2H), 2.53-2.58 (m, 2H), 2.51-2.52 (m, 2H), 2.15 (s, 3H), 1.18 (t, J=7.4 Hz, 3H);
MS m/z (ESI): 364.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(4-methyl-4H-1,2,4-triazol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 1.
1H NMR (400 MHz, DMSO-d6) δ 11.75 (s, 1H), 8.48 (s, 2H), 7.75 (s, 1H), 7.60 (s, 1H), 6.25 (s, 1H), 3.75 (s, 2H), 3.57 (s, 3H), 3.10-3.25 (m, 2H), 2.61-2.74 (m, 2H), 2.51-2.60 (m, 4H), 1.20 (t, J=7.4 Hz, 3H);
MS m/z (ESI): 351.2 [M+H]+.
The preparation method of 1′-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-N,2-dimethyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 418.2 [M+H]+.
The preparation method of 2-chloro-1′-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
1H NMR (400 MHz, DMSO-d6) δ 11.80 (s, 1H), 8.82 (d, J=2.8 Hz, 1H), 8.70 (s, 1H), 7.98 (d, J=1.8 Hz, 1H), 7.90 (d, J=1.8 Hz, 1H), 7.75 (s, 1H), 7.60 (s, 1H), 6.80 (s, 1H), 3.76 (s, 2H), 3.114-3.24 (m, 2H), 2.85 (d, J=4.8 Hz, 3H), 2.65-2.70 (m, 2H), 2.43-2.61 (m, 4H), 1.20 (t, J=7.2 Hz, 3H);
MS m/z (ESI): 438.2 [M+H]+.
The preparation method of N-cyano-1′-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 415.2 [M+H]+.
The preparation method of N-(cyanomethyl)-1′-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
1H NMR (400 MHz, DMSO-d6) δ 11.85 (s, 1H), 9.41-9.48 (m, 1H), 8.75 (s, 1H), 8.40 (s, 1H), 8.01-8.10 (m, 2H), 7.74 (s, 1H), 7.67 (s, 1H), 5.97 (s, 1H), 4.28-4.35 (m, 2H), 3.74 (s, 2H), 3.12-3.21 (m, 2H), 2.70-2.78 (m, 2H), 2.49-2.60 (m, 4H), 1.21 (t, J=7.4 Hz, 3H);
MS m/z (ESI): 429.2 [M+H]+.
The preparation method of N-(1-cyanocyclopropyl)-1′-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
1H NMR (400 MHz, DMSO-d6) δ 11.84 (s, 1H), 9.67 (s, 1H), 8.71 (s, 1H), 8.41 (s, 1H), 8.00-8.04 (m, 2H), 7.76 (s, 1H), 7.65 (d, J=5.6 Hz, 1H), 6.46 (s, 1H), 3.73 (s, 2H), 3.16 (d, J=7.2 Hz, 2H), 2.70-2.73 (m, 2H), 2.53-2.57 (m, 4H), 1.51-1.54 (m, 2H), 1.38-1.40 (m, 2H), 1.22 (t, J=7.2 Hz, 3H);
MS m/z (ESI): 455.2 [M+H]+.
The preparation method of 1′-(1-(7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)cyclopropyl)-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 430.2 [M+H]+.
The preparation method of 1′-(2-(7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)propan-2-yl)-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 432.2 [M+H]+.
The preparation method of 1′-((6-ethyl-7-oxo-7,8-dihydro-1,8-naphthyridin-2-yl)methyl)-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 404.2 [M+H]+.
The preparation method of N-cyclopropyl-1′-((7-cyclopropyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 442.2 [M+H]+.
The preparation method of N-methyl-1′-((6-oxo-7-(prop-1-yn-1-yl)-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 414.2 [M+H]+.
The preparation method of 3-chloro-4-(1-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1,2,3,6-tetrahydropyridin-4-yl)-2-fluoro-N-methylbenzamide refered to Example 1.
MS m/z (ESI): 455.2 [M+H]+.
The preparation method of 4-(1-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1,2,3,6-tetrahydropyridin-4-yl)-2-fluoro-N,3-dimethylbenzamide refered to Example 1.
MS m/z (ESI): 435.2 [M+H]+.
The preparation method of 4-(1-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1,2,3,6-tetrahydropyridin-4-yl)-2,3-difluoro-N-methylbenzamide refered to Example 1.
1H NMR (400 MHz, DMSO-d6) δ 11.84 (s, 1H), 8.41 (s, 1H), 8.34 (s, 1H), 7.76 (s, 1H), 7.65 (s, 1H), 7.35-7.39 (m, 1H), 7.22-7.26 (m, 1H), 6.13 (s, 1H), 3.72 (s, 2H), 3.14 (s, 2H), 2.74-2.81 (m, 3H), 2.64-2.71 (m, 2H), 2.50-2.62 (m, 3H), 2.33 (s, 1H), 1.18 (t, J=7.4 Hz, 3H);
MS m/z (ESI): 439.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(2-methyl-8-(methylamino)-1,7-naphthyridin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 444.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(2-(methyl-d3)-8-(methylamino)-1,7-naphthyridin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 447.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(2-fluoro-8-(methylamino)-1,7-naphthyridin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 448.2 [M+H]+.
The preparation method of 7-((4-(2-chloro-8-(methylamino)-1,7-naphthyridin-3-yl)piperazin-1-yl)methyl)-3-ethyl-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 464.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(6-methyl-8-(methylamino)-1,7-naphthyridin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 444.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(6-(methyl-d3)-8-(methylamino)-1,7-naphthyridin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 447.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(6-fluoro-8-(methylamino)-1,7-naphthyridin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 448.2 [M+H]+.
The preparation method of 7-((4-(6-chloro-8-(methylamino)-1,7-naphthyridin-3-yl)piperazin-1-yl)methyl)-3-ethyl-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 464.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(8-(methylamino)-1,7-naphthyridin-3-yl-6-d)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 431.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(8-(methylamino)-1,7-naphthyridin-3-yl-4-d)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 431.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(8-(methylamino)-5H-pyrido[2,3-d][1,2]oxazin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
MS m/z (ESI): 434.2 [M+H]+.
The preparation method of 5-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)-2-methylisoindoline-1,3-dione refered to Example 3.
MS m/z (ESI): 432.2 [M+H]+.
The preparation method of 6-(4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)-N-methylimidazo[1,5-a]pyridine-1-carboxamide refered to Example 3.
MS m/z (ESI): 446.2 [M+H]+.
The preparation method of 1′-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-5′-fluoro-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 422.2 [M+H]+.
The preparation method of 5-(1-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1,2,3,6-tetrahydropyridin-4-yl)-N-methylthiazole-2-carboxamide refered to Example 1.
MS m/z (ESI): 410.2 [M+H]+.
The preparation method of 1′-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-N-(2,2,2-trifluoroethyl)-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 472.2 [M+H]+.
The preparation method of N-methyl-1′-((6-oxo-7-(trifluoromethyl)-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 444.2 [M+H]+.
The preparation method of 2-chloro-1′-((3-ethyl-2-oxo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)methyl)-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 442.2 [M+H]+
The preparation method of 1′-((3-ethyl-2-oxo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)methyl)-N,2-dimethyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 422.2 [M+H]+.
The preparation method of 2-chloro-1′-((2-ethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)methyl)-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
1H NMR (400 MHz, DMSO-d6) δ 10.62 (s, 1H), 8.61 (d, J=2.8 Hz, 1H), 7.96 (d, J=2.8 Hz, 1H), 7.89 (d, J=2.8 Hz, 1H), 6.86-6.93 (m, 3H), 5.84 (s, 1H), 3.48 (m, 1H), 3.48-3.51 (m, 2H), 3.03-3.06 (m, 2H), 2.81 (d, J=4.9, 3H), 2.63 (t, J=8.0 Hz, 2H), 2.37-2.42 (m, 2H), 1.74-1.82 (m, 2H), 0.99 (t, J=7.4 Hz, 3H);
MS m/z (ESI): 441.2 [M+H]+.
The preparation method of 1′-((2-ethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)methyl)-N,2-dimethyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 421.2 [M+H]+.
The preparation method of 2-chloro-1′-((3-cyclopropyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-7-yl)methyl)-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
1H NMR (400 MHz, DMSO-d6) δ 11.20 (s, 1H), 8.6 (d, J=3.0 Hz, 1H), 7.90 (d, J=2.8 Hz, 1H), 7.75-7.80 (m, 2H), 7.20 (s, 1H), 5.82 (s, 1H), 3.64 (s, 2H), 3.02-3.15 (m, 2H), 2.75 (d, J=4.8 Hz, 3H), 2.52-2.69 (m, 3H), 2.32-2.41 (m, 2H), 0.82-0.98 (m, 2H), 0.58-0.70 (m, 2H);
MS m/z (ESI): 466.2 [M+H]+.
The preparation method of 1′-((3-ethyl-2-oxo-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-7-yl)methyl)-2-fluoro-N-meth yl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 426.2 [M+H]+.
The preparation method of 1′-((3-ethyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-7-yl)methyl)-2-fluoro-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
1H NMR (400 MHz, DMSO-d6) δ 11.42 (s, 1H), 8.71 (s, 1H), 8.03-8.15 (m, 1H), 7.82-7.98 (m, 2H), 7.20-7.30 (m, 2H), 6.28 (s, 1H), 3.84-3.95 (m, 2H), 3.65 (s, 2H), 3.13-3.22 (m, 2H), 2.75 (d, J=4.8 Hz, 3H), 2.50-2.72 (m, 4H), 1.18 (t, J=7.4 Hz, 3H);
MS m/z (ESI): 438.2 [M+H]+.
The preparation method of 1′-((3-ethyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-7-yl)methyl)-N,2-dimethyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
1H NMR (400 MHz, DMSO-d6) δ 11.38 (s, 1H), 8.50 (d, J=2.8 Hz, 1H), 7.83 (d, J=1.8 Hz, 1H), 7.75 (d, J=2.0 Hz, 1H), 7.58 (d, J=2.4 Hz, 1H), 7.10-7.21 (m, 2H), 5.60 (s, 1H), 3.79-3.92 (m, 2H), 3.60 (s, 2H), 3.11-3.15 (m, 2H), 2.75 (d, J=5.0 Hz, 3H), 2.62-2.71 (m, 2H), 2.48 (s, 3H), 2.25-2.40 (m, 2H), 1.12 (t, J=7.2 Hz, 3H);
MS m/z (ESI): 434.2 [M+H]+.
The preparation method of 1′-(1-(7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)ethyl)-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
1H NMR (400 MHz, DMSO-d6) δ 11.82 (s, 1H), 8.67-8.73 (m, 2H), 8.46 (s, 1H), 7.96 (d, J=8.5 Hz, 2H), 7.76 (s, 1H), 7.64 (s, 1H), 6.43 (s, 1H), 3.72 (q, J=6.8 Hz, 1H), 3.09-3.11 (m, 2H), 2.81 (d, J=4.7 Hz, 3H), 2.64 (t, J=10.0 Hz, 3H), 2.52-2.58 (m, 3H), 1.40 (d, J=6.5 Hz, 3H), 1.18 (t, J=7.4 Hz, 3H);
MS m/z (ESI): 418.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(5-fluoro-8-(methylamino)-1,7-naphthyridin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
1H NMR (400 MHz, DMSO-d6) δ 11.85 (s, 1H), 8.71 (d, J=2.7 Hz, 1H), 8.40 (d, J=1.6 Hz, 1H), 7.78 (d, J=2.2 Hz, 1H), 7.74 (s, 1H), 7.62 (s, 1H), 7.22-7.25 (m, 2H), 3.62-3.65 (m, 2H), 3.39-3.43 (m, 4H), 2.93 (d, J=4.8 Hz, 3H), 2.54-2.58 (m, 4H), 2.49-2.52 (m, 2H), 1.17 (t, J=7.4 Hz, 3H);
MS m/z (ESI): 448.2 [M+H]+.
The preparation method of 1′-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-N,5′-dimethyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 418.2 [M+H]+.
The preparation method of 5′-chloro-1′-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 438.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(8-(methylamino)-1,7-naphthyridin-3-yl-5-d)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
1H NMR (400 MHz, DMSO-d6) δ 11.86 (s, 1H), 8.64 (d, J=2.8 Hz, 1H), 8.42 (d, J=1.7 Hz, 1H), 7.77 (d, J=4.9 Hz, 2H), 7.64 (s, 1H), 7.29-7.32 (m, 2H), 3.64-3.67 (m, 2H), 2.95 (d, J=4.9 Hz, 3H), 2.58-2.61 (m, 4H), 2.55 (d, J=7.4 Hz, 2H), 2.51-2.53 (m, 4H), 1.19 (t, J=7.4 Hz, 3H);
MS m/z (ESI): 431.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(8-((methyl-d3)amino)-1,7-naphthyridin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
1H NMR (400 MHz, DMSO-d6) δ 11.79 (s, 1H), 8.57 (d, J=2.7 Hz, 1H), 8.35 (s, 1H), 7.70 (d, J=5.7 Hz, 2H), 7.57 (s, 1H), 7.23 (d, J=2.6 Hz, 2H), 6.62 (d, J=5.9 Hz, 1H), 3.55-3.60 (m, 2H), 3.25-3.31 (m, 4H), 2.47-2.53 (m, 4H), 2.48 (d, J=7.4 Hz, 2H), 1.12 (t, J=7.4 Hz, 3H);
MS m/z (ESI): 433.3 [M+H]+.
The preparation method of 3-ethyl-7-((4-(4-isopropyl-8-(methylamino)-1,7-naphthyridin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
1H NMR (400 MHz, DMSO-d6) δ 11.86 (s, 1H), 8.62 (s, 1H), 8.41 (s, 1H), 7.82 (d, J=6.1 Hz, 1H), 7.74 (s, 1H), 7.61 (s, 1H), 7.48-7.54 (m, 1H), 7.05 (d, J=6.1 Hz, 1H), 3.78-4.03 (m, 2H), 3.62-3.66 (m, 2H), 2.89-3.07 (m, 8H), 2.55-2.62 (m, 4H), 1.40 (d, J=7.0 Hz, 6H), 1.16 (t, J=7.3 Hz, 3H);
MS m/z (ESI): 472.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(2-isopropyl-8-(methylamino)-1,7-naphthyridin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
1H NMR (400 MHz, DMSO-d6) δ 11.87 (s, 1H), 8.42 (s, 1H), 7.80 (d, J=5.7 Hz, 1H), 7.75 (s, 1H), 7.63 (s, 1H), 7.60 (s, 1H), 7.21-7.24 (m, 1H), 6.74 (d, J=5.8 Hz, 1H), 3.64-3.69 (m, 2H), 3.46-3.66 (m, 2H), 2.87-3.04 (m, 8H), 2.52-2.69 (m, 4H), 1.27 (d, J=6.6 Hz, 6H), 1.18 (t, J=7.4 Hz, 3H);
MS m/z (ESI): 472.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(5-methyl-8-(methylamino)-1,7-naphthyridin-3-yl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 3.
1H NMR (400 MHz, DMSO-d6) δ 11.86 (s, 1H), 8.65 (d, J=2.6 Hz, 1H), 8.42 (d, J=1.6 Hz, 1H), 7.76 (s, 1H), 7.63-7.64 (m, 2H), 7.21 (d, J=2.6 Hz, 1H), 7.15 (s, 1H), 3.64-3.68 (m, 2H), 3.39-3.42 (m, 4H), 2.93 (d, J=4.8 Hz, 3H), 2.57-2.61 (m, 4H), 2.52-2.58 (m, 2H), 2.27 (s, 3H), 1.19 (t, J=7.4 Hz, 3H);
MS m/z (ESI): 444.2 [M+H]+.
The preparation method of 3-ethyl-7-((4-(8-(methylamino)-1,7-naphthyridin-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl)-1,5-naphthyridin-2(1H)-one refered to Example 1.
1H NMR (400 MHz, DMSO-d6) δ 11.84 (s, 1H), 8.92 (d, J=2.2 Hz, 1H), 8.43 (d, J=1.7 Hz, 1H), 8.06 (d, J=2.2 Hz, 1H), 7.90 (d, J=5.8 Hz, 1H), 7.76 (s, 1H), 7.66 (s, 1H), 7.57 (q, J=4.7 Hz, 1H), 6.84 (d, J=5.8 Hz, 1H), 6.53 (s, 1H), 3.70-3.74 (m, 2H), 3.19 (d, J=2.6 Hz, 2H), 2.99 (d, J=4.9 Hz, 3H), 2.72-2.75 (m, 2H), 2.58-2.62 (m, 2H), 2.51-2.57 (m, 2H), 1.19 (t, J=7.4 Hz, 3H);
MS m/z (ESI): 427.2 [M+H]+.
The preparation method of 1′-(7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridine-3-yl)-N-methyl-1′,2′,3′,6′-tetrahydro-[3,4′-bipyridine]-6-carboxamide refered to Example 1.
MS m/z (ESI): 418.2 [M+H]+.
The present invention is further illustrated below in combination with the following test examples, which are not intended to limit the scope of the present invention.
The experimental objective of this Test Example is to determine the inhibitory activity of the compounds on PARP1 enzyme.
The inhibitory activity of the compounds on PARP1 enzyme was determined by the chemiluminescence method in the experiment. The experiment was carried out in a 384-well plate. Coating histones in a 384-well plate: 5×histone solution was diluted 5 folds with PBS, added to a 384-well ELISA plate (25 μL per well), and incubated at 4° C. overnight. The coated ELISA plate was rinsed with 1×PBST buffer, blocked with the blocking buffer (Blocking buffer 3 in the kit, 100 μL per well) for 30 to 120 minutes, and rinsed with 1×PBST buffer 3 to 6 times. A mixture of PARP reaction biotin-labeled substrate, activated DNA, 10×PARP buffer and water was added (12.5 μL per well). Compound solutions with different concentrations were formulated using the experimental buffer (10% DMSO aqueous solution containing 1.25 mM DTT). The final detection concentration started from 100 nM, with 3-fold dilution and 8 concentrations. The compound solutions were added to the reaction wells of the 384-well plate (2.5 μL per well). 2.5 μL of 10% DMSO aqueous solution containing 1.25 mM DTT was added to the positive control well and blank well (2.5 μL per well). 10 μL of PARP1 enzyme solution formulated with 1×PARP buffer was added to start the reaction. The plate was centrifuged at 1000 rpm for 1 minute, and reacted at room temperature for 60 minutes. After completion of the reaction, the reaction solution was poured off, and the plate was rinsed with 1×PBST buffer. Streptavidin-HRP solution diluted 50 folds with Blocking buffer 3 was added (25 μL per well), and the plate was incubated at room temperature for 30 minutes. The reaction solution was poured off, and the plate was rinsed with 1×PBST buffer 3 to 6 times. The luminescence reaction solution obtained by mixing ECL substrate A and ELISA ECL substrate B (1:1) was added (50 μL per well) for reaction. The chemiluminescence values were measured immediately with a BioTek Synergy H1 or Envision instrument.
The chemiluminescence values were measured with a BioTek Synergy H1 or Envision instrument. The inhibition rate was calculated, and the concentration and inhibition rate were fitted to a nonlinear regression curve using Graphpad Prism software to obtain the IC50 value.
The inhibitory activity of some compounds of the examples of the present invention on PARP1 enzyme is shown in the following table:
The compounds of the present invention show excellent biological activity in the PARP1 enzyme inhibition experiment.
The experimental objective of this Test Example is to determine the inhibitory activity of the compounds on PARP2 enzyme.
The inhibitory activity of the compounds on PARP2 enzyme was determined by the chemiluminescence method in the experiment. The experiment was carried out in a 96-well plate. Coating histones in a 96-well plate: 5×histone solution was diluted 5 folds with PBS, added to a 96-well ELISA plate (50 μL per well), and incubated at 4° C. overnight. The coated ELISA plate was rinsed with 1×PBST buffer, blocked with the blocking buffer (Blocking buffer 3 in the kit, 200 μL per well) for 30 to 120 minutes, and rinsed with 1×PBST buffer 3 to 6 times. A mixture of PARP reaction biotin-labeled substrate, activated DNA, 10×PARP buffer and water was added (25 μL per well). Compound solutions with different concentrations were formulated using the experimental buffer (10% DMSO aqueous solution containing 1.25 mM DTT). The final detection concentration started from 10 μM, with 3-fold dilution and 8 concentrations. The compound solutions were added to the reaction wells of the 96-well plate (5 μL per well). 5 μL of 10% DMSO aqueous solution containing 1.25 mM DTT was added to the positive control well and blank well (5 μL per well). 20 μL of PARP2 enzyme solution formulated with 1×PARP buffer was added to start the reaction. The plate was centrifuged at 1000 rpm for 1 minute, and reacted at room temperature for 60 minutes. After completion of the reaction, the reaction solution was poured off, and the plate was rinsed with 1×PBST buffer. Streptavidin-TRP solution diluted 50 folds with Blocking buffer 3 was added (50 μL per well), and the plate was incubated at room temperature for 30 minutes. The reaction solution was poured off, and the plate was rinsed with 1×PBST buffer 3 to 6 times. The luminescence reaction solution obtained by mixing ECL substrate A and ELISA ECL substrate B (1:1) was added (100 μL per well) for reaction. The chemiluminescence values were measured immediately with a BioTek Synergy H1 or Envision instrument.
The chemiluminescence values were measured with a BioTek Synergy H1 or Envision instrument. The inhibition rate was calculated, and the concentration and inhibition rate were fitted to a nonlinear regression curve using Graphpad Prism software to obtain the IC50 value.
The compounds of the present invention show high selectivity for PARP2 in the PARP2 enzyme inhibitory activity experiment.
The experimental objective of this Test Example is to determine the inhibitory effect of the compounds on the proliferation activity of BRCA2 Knockout DLD-1 cells.
BRCA2 Knockout DLD-1 cells were cultured using RPMI1640 culture medium containing 10% FBS to an appropriate cell density. The cells were collected, and adjusted to an appropriate cell concentration using the complete culture medium. The cell suspension was spread on a 96-well plate (90 μL per well), and placed in a 37° C., 5% CO2 incubator overnight. Compound solutions of different concentrations were formulated using DMSO and culture medium, and vehicle control was set up. The compound solutions were added to the 96-well plate (10 μL per well), and the plate was incubated in a 37° C., 5% CO2 incubator for about 144 hours. CellTiter-Glo solution was added, and the plate was shaken to mix evenly, and incubated in the dark for 10 to 30 minutes. The values were measured with a Synergy H1 or Envision microplate reader.
The inhibition rate was calculated using the luminescence signal value. The concentration and inhibition rate were fitted to a nonlinear regression curve using Graphpad Prism software to obtain the IC50 value.
The inhibitory effect of some compounds of the examples of the present invention on the proliferation activity of BRCA2 Knockout DLD-1 cells is shown in the following table:
The compounds of the present invention show excellent biological activity in the BRCA2 Knockout DLD-1 cell proliferation activity inhibition experiment.
The objective of this experiment is to determine the bidirectional permeability of the compounds through Caco-2 cell model.
Liquid chromatography-mass spectrometer, centrifuge, vortexer, pipette, 24-well test plate, acetonitrile solution containing internal standard, Caco-2 cells (ATCC), Hank's balanced salt solution (HBSS), dimethyl sulfoxide (DMSO)
The bidirectional permeability of the compounds of the examples of the present invention through the Caco-2 cell model is shown in the table below:
It can be seen from the experimental results in the above table that the compounds of the examples of the present invention have high permeability.
Balb/C mice were used as test animals. The pharmacokinetic behavior of the compounds of Examples was studied in mouse body (plasma) by orally administration at a dose of 1 mg/kg.
Compounds of the examples of the present invention, prepared by the applicant.
Male Balb/C mice (6 mice per example), purchased from Shanghai Jiesijie Laboratory Animal Co., LTD, with Certificate No.: SCXK (Shanghai) 2013-0006 N0.311620400001794.
5 g of hydroxyethyl cellulose (HEC, CMC-Na, viscosity: 800-1200 Cps) was weighed and dissolved in 1000 mL of purified water, followed by the addition of 10 g of Tween 80. The mixture was mixed well to obtain a clear solution.
2.05 mg of the compound was weighed and dissolved in the solution. The mixture was shaken well, crushed in a cell crusher for 1 minute, and sonicated for 15 minutes to obtain a suspension with a concentration of 0.1 mg/mL.
After an overnight fast, male Balb/C mice were administered p.o. with the test compound at a dose of 1 mg/kg and a volume of 10 mL/kg.
0.04 mL of blood was taken from the orbit of the mouse at 0, 0.5, 1, 2, 4, 6, 8 and 24 hours after the administration. The samples were stored in EDTA-K2 tubes, and centrifuged for 6 minutes at 4° C., 6000 rpm to separate the plasma. The plasma samples were stored at −80° C. The mouse was fed 4 hours after the administration.
The main parameters of pharmacokinetics were calculated by WinNonlin 8.2. The results of pharmacokinetic test in mice are shown in the following table:
It can be seen from the results of pharmacokinetic test in mice in the table that the compounds of the examples of the present invention show good absorption and metabolism properties, both the exposure AUC and maximum plasma concentration Cmax are good.
To evaluate the distribution of the compound in the plasma and tumor, and the inhibitory effect on PAR in tumor tissue after a single oral administration in the human breast cancer cell line MDA-MB-436 subcutaneous xenograft tumor model in nude mice.
BALB/c nude mice, 6 to 8 weeks old, ♀, purchased from the Experimental Animal Management Department of Shanghai Institute of Family Planning
The mice were euthanized by CO2 asphyxiation according to the time of the experimental design, and the samples were collected.
Plasma collection: After the mouse was euthanized, blood was collected from the heart. The collected blood was added to a centrifuge tube containing EDTA-K2. The tube was manually inverted 3 to 4 times, placed on ice, and centrifuged at 8000 rpm at 4° C. for 5 minutes. 100 μL of the centrifuged plasma was transferred to a new labeled centrifuge tube. One aliquot of plasma was quickly freezed on dry ice, and stored in a refrigerator at −80±10° C. for PK test.
Tumor tissue collection: After the blood collection, the tumor tissue was collected. The collected tumor tissue was divided into 3 aliquots (˜0.1 g each), placed into labeled 2 mL centrifuge tubes, and stored in a refrigerator at −80±10° C. for PK or PD test.
The remaining tumor-bearing mice were used to collect blank plasma and blank tumor tissue.
a. Sample Process:
a. Tumor Tissue Sample Lysis
1 mL of tumor lysis solution was added to each tube of tumor tissue sample, followed by the addition of steel beads. The sample was placed into a tissue grinder for tissue homogenization, lysed on ice for 20 minutes, and centrifuged at 10,000 g at 4° C. for 5 minutes. The protein supernatant was collected.
b. Preparation of Protein Sample
Protein quantification was performed by BCA protein quantification kit. According to the concentration, the protein supernatant sample, 10× Sample Reducing Agent, 4×LDS Sample Buffer and lysate were formulated into protein loading solution with consistent concentration. The protein loading solution was placed into a preheated dry thermostat, and incubated at 100° C. for 10 minutes to denature the protein.
c. Western Blot Experiment of the Protein Sample
In the MDA-MB-436 (breast cancer, BRCA1 mutation) model, the plasma concentration of the compound of Example 1 within 24 hours after a single administration was higher than that of AZD5305, and the inhibition of intratumoral PAR was comparable. The single administration of the compound of Example 1 can inhibit intratumoral PAR for 72 hours, which is better than AZD5305.
To evaluate the in vivo efficacy of the compounds in human colorectal cancer cell line DLD-1 BRCA2−/− subcutaneous xenograft tumor model in nude mice.
BALB/c nude mice, 6 to 8 weeks old, 9, purchased from the Experimental Animal Management Department of Shanghai Institute of Family Planning
Calculation of tumor volume: tumor volume (mm3)=length (mm)×width (mm)×width (mm)/2
Compounds of Examples 1, 3, 29, 35 and 46 of the present invention show excellent tumor inhibitory effect in this model experiment, and their tumor growth inhibition rate TGI (%) is >90%, the tumor growth inhibition rate TGI (%) of the preferred compounds is >150%, and there is no significant decrease in animal's body weight.
| Number | Date | Country | Kind |
|---|---|---|---|
| 202110443582.0 | Apr 2021 | CN | national |
| 202110653169.7 | Jun 2021 | CN | national |
| 202110808316.3 | Jul 2021 | CN | national |
| 202110926676.3 | Aug 2021 | CN | national |
| 202210072358.X | Jan 2022 | CN | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2022/088466 | 4/22/2022 | WO |
